VIB and Flemish Minister of Economy and Innovation, Hilde Crevits, announce the appointment of Dr Christine Durinx as VIB’s co-managing director, alongside Dr Jérôme Van Biervliet. Dr Jo Bury, co-founder and co-managing director since VIB’s inception 25 years ago, is passing the torch to Durinx who is the former Executive Director of the SIB Swiss Institute of Bioinformatics.
TWB partners with Processium and Syngulon
Latest NewsIndustrial biotech project managment specialist Toulouse White Biotech (TWB) has joined forces with process developer Processium and industrial synbio start-up Syngulon.
Meat consumption must fall by at least 75 percent
Latest NewsIf our planet is to continue feeding us in the future, rich countries must significantly reduce their meat consumption by at least 75% suggests a new study by German researchers.
Vigeneron updates gene therapy collab with Daiichi Sankyo
Latest NewsViGeneron and Daiichi Sankyo have agreed a follow-on collaboration to evaluate vgAAVs as vectors for Daiichi Sankyo’ novel treatment of prevalent eye diseases.
Single-use market to reach $20.8bn by 2026
Latest NewsAnalysts from Markets & Markets today released the report "Single use Bioprocessing Market by Product.
Study shows advantages of cellular agriculture
Latest NewsNovel foods derived from cell culture instead of animals reduce the environmental impact of diets, water and land use by 80%, report Finnish researchers.
International expertise returns to Belgium
AppointmentsVIB and Flemish Minister of Economy and Innovation, Hilde Crevits, announce the appointment of Dr Christine Durinx as VIB’s co-managing director, alongside Dr Jérôme Van Biervliet. Dr Jo Bury, co-founder and co-managing director since VIB’s inception 25 years ago, is passing the torch to Durinx who is the former Executive Director of the SIB Swiss Institute of Bioinformatics.
EMA delays Valneva vaccine approval
Latest NewsThe approval of Valneva’s Corona vaccine is delaying. The European Medicines Agency’s CHMP requested additional data.
Mimetas BV participating in €325m cancer funding
Latest NewsOrgan-on-chip disease model specialist Mimentas BV participates in a €325m funding to accelerate preclinical cancer R&D in the Netherlands.
Hansa Biopharma’s imlifidase advances to Phase III testing
Latest NewsThe US Food & Drug Administration has given the green light for Phase III testing of Hansa Biopharma’s imlifidase in anti-GBM disease.
GSK acquires Sierra Oncology for 1.9bn
Latest NewsGlaxoSmithKline acquires California-based Sierra Oncology and a ready-for-approval product candidate for myelofibrosis.